What's New

Medical News
& Alerts

Conferences
& Meetings


Other Medical
Resources

Employment
Opportunities

Partnering
Opportunities

Search results for: Carboplatin
95%DGNews: Delayed Symptom Progression, Better Tolerability Found With Pegylated Liposomal Doxorubicin Plus Carboplatin for Ovarian Cancer: Presented at ASCO
95%DGNews: Carboplatin Hypersensitivity High in Children, But Does Not Affect Progression-Free Survival Rate for Low-Grade Glioma: Presented at ASCO
95%DGNews: Carboplatin As Effective As Standard Combination Therapy For Advanced Ovarian Cancer
95%DGNews: Phase II Clinical Trials Results of RMP-7 and Carboplatin
94%DGNews: Cisplatin Is More Effective Than Carboplatin for Treating Non-Small-Cell Lung Cancer
94%DGNews: FDA Approves Lilly's Gemzar (Gemcitabine HCl) for Ovarian Cancer Treatment
94%DGNews: InterMune Discontinues Ovarian Cancer Trial With Actimmune (Interferon Gamma-1b)
94%DGNews: CFS: Pemetrexed Doublets Show Promise in Advanced Non-Small-Cell Lung Cancer
94%DGNews: Drug Prevents Hearing Loss Caused By Brain Tumor Therapy
93%DGNews: Gefitinib Shows Significant Survival Benefits Over Carboplatin/Paclitaxel in First-Line Treatment of NSCLC: Presented at ECCO-ESMO
93%DGNews: Phase 3 Trial of Sorafenib in Patients With Non-Small-Cell Lung Cancer Halted
93%DGNews: Older Cancer Patients in the Community Setting Can Benefit From Pegfilgrastim
93%DGNews: SGO: Weekly Docetaxel and Carboplatin Effective and Well Tolerated in Recurrent Ovarian and Peritoneal Cancer
93%DGNews: Gemzar (Gemcitabine) Combination Therapy Receives European Approvals for Treatment of Ovarian Cancer
93%DGNews: ASCO: Adding Carboplatin to Paclitaxel and Trastuzumab Improves Response Rates in HER-2 Positive Breast Cancer
93%DGNews: AACR: Paclitaxel Carboplatin Combination Therapy Might Be as Effective as Mitoxantrone Alone for Patients With Hormone-Refractory Prostate Cancer
93%DGNews: SABCS: Addition of Paraplatin (Carboplatin) Enhances Effectiveness of Treatment for Advanced Breast Cancer
93%DGNews: ESMO: Carboplatin + Gemcitabine Equivalent to Vinorelbine + Gemcitabine in NSCLC
93%DGNews: ECCO11: Addition of Topotecan to Paclitaxel/Carboplatin Combo Reduces Toxicity, Maintains Efficacy for Advanced Ovarian Cancer
93%DGNews: ASCO MEETING: Taxol Plus Carboplatin Fails To Show Clinical Advantage Over Standard Regimen In NSCLC
93%DGNews: ECCO: Hycamtin Effective In Combination Therapy For Ovarian Cancer
92%DGNews: Mutation Status Appears to Predict Response to First-Line Gefitinib Treatment for Non-Small-Cell Lung Cancer: Presented at ASCO
92%DGNews: Single Dose of Chemotherapy Is as Effective as Radiotherapy for Testicular Cancer
92%DGNews: ICACT: Medium Dose Cisplatin-Gemcitabine-Carboplatin Triplet as Effective as Standard Doublet in Stage IV Non-Small Cell Lung Cancer
92%DGNews: Newer Lung Cancer Treatments Extend Survival Longer Than Traditional Regimens
92%DGNews: ASCO MEETING: Taxol/Paraplatin Treatment Less Toxic For Advanced Ovarian Cancer Patients
91%DGNews: Gefitinib Promising for Treatment of Non-Small-Cell Lung Cancer: Presented at ESMO
91%DGNews: Breast Cancer Patients Achieve 16-Month Progression-Free Survival With Nab-Paclitaxel, Carboplatin, and Trastuzumab: Presented at ASCO
91%DGNews: Avastin (Bevacizumab, rhuMAb-VEGF) Appears to Extend Life Also for Lung Cancer Patients
91%DGNews: ICACT: Second-Line Paclitaxel and Carboplatin Show Promising Results in Advanced Gastric Cancer
91%DGNews: ICACT: Oxaliplatin Plus Gemcitabine Show Activity and Safety in Patients With Advanced Non-Small-Cell Lung Cancer
91%DGNews: ERRATUM: AACR: Paclitaxel Carboplatin Combination Therapy Might Be as Effective as Mitoxantrone Alone for Patients With Hormone-Refractory Prostate Cancer
91%DGNews: CFS: Weekly Paclitaxel and Carboplatin Benefits Elderly Patients with Lung Cancer
91%DGNews: AAO: Carboplatin-Vincristine Regimen Without Etoposide Treats Paediatric Intraocular Retinoblastoma
91%DGNews: WCLC:Taxane Regimen as Effective and Safe in Elderly Patients with Advanced Non-Small Cell Lung Cancer as in Younger Patients
91%DGNews: WCLC: Doublet Regimen Shows Good Efficacy and Tolerability in Elderly Patients with Non-Small Cell Lung Cancer
91%DGNews: IBCC: Platinum Compounds May Become Adjuvant Therapy for Breast Cancer
91%DGNews: ASCO: Gemcitabine and Paclitaxel Followed by Carboplatin Demonstrates Efficacy in Urothelial Cancers
91%DGNews: DG DISPATCH - ICACT: Neurotoxicity Decreased With Paclitaxel Split-Dose Regimen
90%DGNews: Dose-Dense Chemotherapy Improves Survival in Advanced Ovarian Cancer
90%DGNews: Combination Belinostat and Platinum-Based Therapy Shows Efficacy for Relapsed Epithelial Ovarian Cancer: Presented at ASCO
90%DGNews: Comparing Preoperative and Perioperative Chemotherapies: Presented at ELCC
90%DGNews: Intensifying Treatment With Paclitaxel and Carboplatin Does Not Improve Time to Progression in Advanced Ovarian Cancer Patients: Presented at SGO
90%DGNews: Update on Survival in a Phase 1b/2 Study of DMXAA (AS1404) Combine With Carboplatin and Paclitaxel in Non-Small-Cell Lung Cancer: Presented at AACR-NCI-EORTC
90%DGNews: SGO: Weekly Paclitaxel and Carboplatin Shows Effect, Favourable Toxicity for Salvage Treatment in Cervical and Endometrial Cancer
90%DGNews: ESMO: Carboplatin, Capecitabine and Docetaxel Combination Shows Favourable Results in Patients With Advanced Gastric or Gastroesophageal Adenocarcinoma
90%DGNews: ERS: Weekly Chemotherapy Schedule 'Slightly Superior' to Standard Regimen For Non-Small-Cell Lung Cancer
90%DGNews: ASCO: Different Ethnicities React Differently to Same Chemotherapy Regimen
90%DGNews: ASCO: Adjuvant Therapy With One-Day Course of Carboplatin is as Effective as Standard Radiation for Prevention of Recurrent Testicular Seminoma
90%DGNews: SABCS: Weekly Chemotherapy Schedule Safer Than Three-Week Schedule
Enter keywords you wish to find information about:

Search for documents that contain:
any of these words.
this exact phrase.
all of these words.

 

 

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.

All contents Copyright (c) 1998 PSL Consulting Group Inc.
all rights reserved.